Medipal named Imagawa CEO while analysts hold Medipal stock
Published on 10/13/2026 at 01:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Medipal named Kuniaki Imagawa president and CEO effective October 1, 2026.
- The latest analyst rating was Hold with a JPY 2,900 price target.
- First-quarter fiscal 2027 revenue reached JPY 989.50 billion and earnings were JPY 13.65 billion.
- The last Lang & Schwarz price was EUR 16.65 on October 12, 2026.
Medipal (ISIN JP3268950007) had named Kuniaki Imagawa representative director, president and CEO effective October 1, 2026, according to The Globe and Mail. The same report listed the latest analyst rating as Hold with a JPY 2,900 price target. Medipal was last at EUR 16.65 at Lang & Schwarz on October 12, 2026 at 11:00 p.m. CEST.
Leadership change supports continuity
Imagawa previously led Mediceo Corporation and oversaw the pharmaceutical business, while former president and CEO Shuichi Watanabe moved to chairman and retained the chief compliance officer role, The Globe and Mail reported. The arrangement places pharmaceutical operations and group governance under a revised senior-management structure.
For investors, the key change is the combination of a new group chief executive and a continuing compliance role for Watanabe. That split keeps experienced oversight in place while Imagawa takes responsibility for the next phase of execution.
First-quarter revenue reached JPY 989.50 billion
Medipal generated JPY 989.50 billion of revenue and JPY 13.65 billion of earnings in the first quarter of fiscal 2027, according to Yahoo Finance. The reported profit margin was 1.38 percent for that period, giving the leadership transition a clearly quantified operating backdrop.
The analyst picture is restrained rather than uniform. Investing.com showed four analysts with a JPY 3,145 average 12-month target, alongside a JPY 2,900 to JPY 3,600 target range and one Buy against three Hold ratings.
What does the change mean for execution?
The leadership handover arrives as Medipal manages a large distribution platform spanning prescription pharmaceuticals, medical equipment and everyday goods. Its first-quarter revenue and earnings figures provide the operating baseline against which Imagawa's tenure will be assessed.
The last available euro quotation was EUR 16.65 at Lang & Schwarz on October 12, 2026 at 11:00 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Medipal stock.
Medipal stock facts
- Company: MediPal Holdings Corporation
- ISIN: JP3268950007
- Ticker: 7459
- Primary exchange: Tokyo Stock Exchange
- Last price Lang & Schwarz as of October 12, 2026, 11:00 p.m. CEST: EUR 16.65
- Market capitalization: JPY 604.6 billion as of October 9, 2026
- 52-week range: JPY 2,456.50-3,182.00 as of October 9, 2026
- Sector / Industry: Healthcare / Medical Distribution
Market context: Market report Nikkei 225.
